Jude Total Therapy Study XV, only low-risk B-ALL patients with ETV6-RUNX1 positivity or hyperdiploidy and negative MRD (<10–4) on day 19 of remission induction have a low cumulative risk of relapse (1.9% and 3.8%, respectively) compared to an unacceptably high cumulative risk of relapse (9.5%) in low-risk patients with other genotypes and negative MRD on day 19 (38). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.